Guido Dalbagni
Overview
Explore the profile of Guido Dalbagni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
6139
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Teo M, Guercio B, Arora A, Hao X, Regazzi A, Donahue T, et al.
Clin Genitourin Cancer
. 2022 Jun;
20(5):431-441.
PMID: 35676169
Introduction: Small cell carcinoma of the bladder (SCCB) is a rare variant of bladder cancer with poor outcomes. We evaluated long-term outcomes of nonmetastatic (M0) and metastatic (M1) SCCB and...
12.
Letica-Kriegel A, Tin A, Nash G, Benfante N, McNeil N, Vickers A, et al.
Eur J Surg Oncol
. 2022 Mar;
48(6):1427-1432.
PMID: 35304038
Background: Retrospective studies have shown the beneficial impact of geriatric comanagement (GERICO) on perioperative outcomes of older adults with cancer. We prospectively assessed the feasibility of perioperative GERICO for older...
13.
Jensen B, Jensen J, Love-Retinger N, Bowker M, Retinger C, Dalbagni G
Urol Nurs
. 2022 Feb;
39(6):303-313.
PMID: 35221640
Background: Radical cystectomy(RC) often leads to postoperative morbidity and complications. We conducted a pilot study on the effectiveness of multimodal prehabilitation, a preoperative conditioning method shown to be effective for...
14.
Teo M, Al-Ahmadie H, Seier K, Tully C, Regazzi A, Pietzak E, et al.
Br J Cancer
. 2022 Feb;
126(8):1236.
PMID: 35145255
No abstract available.
15.
Furberg H, Petruzella S, Whiting K, Stein E, Orlow I, Kenney J, et al.
J Urol
. 2022 Jan;
207(6):1200-1206.
PMID: 35084998
Purpose: Our goal was to determine the association between biochemically verified post-diagnosis smoking exposure and nonmuscle-invasive bladder cancer (NMIBC) recurrence risk. Materials And Methods: We conducted a prospective study of...
16.
Herr H, Vertosick E, Dalbagni G, Cha E, Smith R, Benfante N, et al.
Urology
. 2021 Jul;
157:197-200.
PMID: 34274387
Objective: To test whether 2 sequential BCG-induction courses improve the response of high-risk non-muscle invasive bladder cancer. Achieving a complete response (CR) to BCG is critical to disease-free survival. Patients...
17.
Comperat E, Amin M, Epstein J, Hansel D, Paner G, Al-Ahmadie H, et al.
Adv Anat Pathol
. 2021 Jun;
28(4):196-208.
PMID: 34128484
The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder cancer focusing on important topics of high interest for the practicing surgical pathologist and urologist....
18.
Amin M, Comperat E, Epstein J, True L, Hansel D, Paner G, et al.
Adv Anat Pathol
. 2021 Jun;
28(4):179-195.
PMID: 34128483
The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder neoplasia with a focus on issues relevant to the practicing surgical pathologist for the understanding...
19.
Damrauer J, Roell K, Smith M, Sun X, Kirk E, Hoadley K, et al.
Clin Cancer Res
. 2021 Jun;
27(16):4599-4609.
PMID: 34117034
Purpose: Improved risk stratification and predictive biomarkers of treatment response are needed for non-muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling...
20.
Almassi N, Vertosick E, Sjoberg D, Wong N, Huang C, Pietzak E, et al.
BJU Int
. 2021 Apr;
129(4):463-469.
PMID: 33866683
Objective: To evaluate whether urothelial carcinoma (UC) with sarcomatoid differentiation is associated with a lower pathological response rate to neoadjuvant chemotherapy (NAC) and worse oncological outcomes compared to UC without...